Start the conversation
Bellicum Pharmaceuticals Inc. (Nasdaq: BLCM) is another company that develops therapies for cancer patients. BLCM looks to raise $100 million this week by offering 6.3 million shares at a $15 to $17 range. In the last year, BLCM had revenue of just $3 million. BLCM will begin trading Thursday, Dec. 18.